Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.

Antimicrobial agents and chemotherapy - 1 Mar 2007

Livermore David M, Warner Marina, Mushtaq Shazad, North Sarah, Woodford Neil

Abstract excerpt

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Drug Resistance, Bacterial
Share to Enterococcus faecalis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enterococcus faecium

Share to Linezolid

Share to Methicillin Resistance

Share to Oxazolidinones

Share to Staphylococcus aureus

Source

Open in PubMed Open full text

Identifiers

PMID: 17210773
DOI: 10.1128/AAC.01347-06
PMCID: PMC1803128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.PMID 17210773Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

Oxazolidinones: activity, mode of action, and mechanism of resistance.Semantic proximity Read ↗

Mechanism of action of the oxazolidinone antibacterial agentsSemantic proximity Read ↗

Oxazolidinones: Mechanism of action and molecular characterization of resistance mechanisms in staphylococciSemantic proximity Read ↗

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsSemantic proximity Read ↗

Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.Semantic proximity Read ↗

Rχ-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid ResistanceSemantic proximity Read ↗

The oxazolidinones: past, present, and future.Semantic proximity Read ↗

In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosisSemantic proximity Read ↗

Tedizolid for the Management of Human Infections: In Vitro CharacteristicsSemantic proximity Read ↗

Linezolid Resistance in StaphylococciSemantic proximity Read ↗

WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.